We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
Cap. Flow
-$34.7M
Cap. Flow %
-23.28%
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$2.73M
2
PFE icon
Pfizer
PFE
+$2.42M
3
ARGX icon
argenx
ARGX
+$2.33M
4
VYNE icon
VYNE Therapeutics
VYNE
+$2.08M
5
QQQM icon
Invesco NASDAQ 100 ETF
QQQM
+$1.95M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$3.38M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$2.95M
3
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$2.75M
4
TSVT
2seventy bio
TSVT
+$2.58M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 59.47%
2 Real Estate 11.94%
3 Financials 4.93%
4 Consumer Discretionary 2.41%
5 Industrials 2.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERE
51
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.06M 0.71%
+25,000
New +$718K
STXS icon
52
Stereotaxis
STXS
$154M
$1.05M 0.7%
600,000
– –
KPTI icon
53
Karyopharm Therapeutics
KPTI
$216M
$973K 0.65%
75,000
– –
SHY icon
54
iShares 1-3 Year Treasury Bond ETF
SHY
$25.7B
$930K 0.62%
11,340
-33,850
-75% -$2.75M
ONIT
55
Onity Group
ONIT
$344M
$867K 0.58%
28,195
– –
MBLY icon
56
Mobileye
MBLY
$7.76B
$866K 0.58%
20,000
– –
AGNC icon
57
AGNC Investment
AGNC
$12.9B
$830K 0.56%
84,646
– –
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$4.38B
$814K 0.55%
26,000
-24,000
-48% -$573K
OMCL icon
59
Omnicell
OMCL
$2.09B
$753K 0.51%
20,000
+5,000
+33% +$184K
GILD icon
60
Gilead Sciences
GILD
$167B
$689K 0.46%
8,500
– –
PTGX icon
61
Protagonist Therapeutics
PTGX
$9.06B
$688K 0.46%
30,000
-13,500
-31% -$236K
NUVB icon
62
Nuvation Bio
NUVB
$2.02B
$680K 0.46%
450,000
+40,000
+10% +$51.5K
ROIV icon
63
Roivant Sciences
ROIV
$24.8B
$618K 0.41%
55,000
+20,000
+57% +$195K
IRTC icon
64
iRhythm Holdings
IRTC
$3.64B
$535K 0.36%
5,000
-2,000
-29% -$174K
IEI icon
65
iShares 3-7 Year Treasury Bond ETF
IEI
$18.2B
$535K 0.36%
+4,568
New +$521K
HLX icon
66
Helix Energy Solutions
HLX
$1.41B
$514K 0.35%
50,000
-10,000
-17% -$99.3K
CAH icon
67
Cardinal Health
CAH
$53.5B
$509K 0.34%
5,053
+218
+5% +$21.6K
BBJP icon
68
JPMorgan BetaBuilders Japan ETF
BBJP
$17.1B
$501K 0.34%
9,545
-1,430
-13% -$72.7K
EWA icon
69
iShares MSCI Australia ETF
EWA
$1.43B
$491K 0.33%
+20,188
New +$447K
NNDM
70
Nano Dimension
NNDM
$326M
$480K 0.32%
200,000
– –
PCAR icon
71
PACCAR
PCAR
$66.4B
$451K 0.3%
4,618
+2,018
+78% +$181K
AUPH icon
72
Aurinia Pharmaceuticals
AUPH
$2.05B
$450K 0.3%
50,000
– –
SOUN icon
73
SoundHound AI
SOUN
$2.73B
$424K 0.28%
200,000
– –
VTRS icon
74
Viatris
VTRS
$20.1B
$379K 0.25%
35,000
-12,500
-26% -$120K
CWB icon
75
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.78B
$378K 0.25%
5,242
-592
-10% -$40.2K
1 2
3
4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.

  • AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
  • AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
  • AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
  • AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
  • AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
  • AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
  • AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.